2. >>R&D
  3. >>Clinical Trials

Roche On Track To Supplement Relaunched Susvimo’s Label

 
• By Joseph Haas

Having relaunched Susvimo for wet AMD, Roche now has the ocular implant under FDA review for approval in two diabetic ophthalmic indications and presented two-year data in those settings.

DME
Roche hopes to add two diabetes-related eye diseases to the Susvimo label • Source: Shutterstock

Now back on the market as a refillable ocular implant for wet age-related macular degeneration (AMD), Roche Holding AG/Genentech, Inc. ‘s Susvimo (ranibizumab injection) may be poised to add indications in diabetic macular edema (DME) and diabetic retinopathy (DR) as Roche seeks to build up the product as a complement to its blockbuster wet AMD, DME and retinal vein occlusion therapy Vabysmo (faricimab).

Initially approved in the US to treat wet AMD in 2021, the implant was pulled from the market in 2022...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Ophthalmology

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

 
• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.

Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD

 
• By Alaric DeArment

The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.